achieve life sciences - Die letzten 30 Beiträge
eröffnet am 24.06.18 15:20:22 von
neuester Beitrag 10.01.23 19:02:02 von
neuester Beitrag 10.01.23 19:02:02 von
Beiträge: 1.058
ID: 1.283.149
ID: 1.283.149
Aufrufe heute: 0
Gesamt: 95.849
Gesamt: 95.849
Aktive User: 0
ISIN: US0044685008 · WKN: A2QAR3 · Symbol: ACHV
4,5750
USD
+0,77 %
+0,0350 USD
Letzter Kurs 25.04.24 Nasdaq
Neuigkeiten
25.04.24 · globenewswire  |
11.04.24 · globenewswire |
28.03.24 · globenewswire |
20.03.24 · globenewswire |
14.03.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,000 | +25,00 | |
| 6,0000 | +25,00 | |
| 0,7113 | +21,90 | |
| 0,6400 | +18,52 | |
| 1,1100 | +15,70 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 9,7200 | -19,60 | |
| 0,7350 | -20,97 | |
| 4,0000 | -27,27 | |
| 2,7280 | -29,14 | |
| 14,510 | -32,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
https://finance.yahoo.com/news/achieve-life-sciences-announc…
https://finance.yahoo.com/news/achieve-life-sciences-announc…
Seid ihr hier noch dabei?
Achieve Life Sciences
Achieve Life Sciences: Gute Daten, aber...?
https://www.finanznachrichten.de/nachrichten-2022-04/5588723…
Achieve Life Sciences: Gute Daten, aber...?
https://www.finanznachrichten.de/nachrichten-2022-04/5588723…
Achieve Life Sciences kündigt Kreditfazilität in Höhe von 25 Millionen US-Dollar von der Silicon Valley Bank zur Finanzierung der klinischen Entwicklung der Cytisinicline-Raucherentwöhnung an
https://achievelifesciences.com/2021/12/22/achieve-announces…
https://achievelifesciences.com/2021/12/22/achieve-announces…
Antwort auf Beitrag Nr.: 68.964.469 von liquidx am 05.08.21 09:41:19kommt halt drauf an, wie du ausgestattet bist und zu welchen Preisen du eingekauft hast.
Trading Spotlight
Ich würde noch warten. Sie haben jetzt zwar die benötigte Anzahl an Studienteilnehmern, aber die Topline Ergebnisse sind für H1‘22 angekündigt.
Ist noch jemand dabei? Wäre ein Nachkauf nun gut?
Dann ist hier wohl erst mal die Luft raus... Mal sehen, wann ich mein EK je wieder sehe.
Was ist denn hier los?
SEATTLE, Wash and VANCOUVER, British Columbia, April 22, 2021 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be hosting a Virtual Non-Deal Roadshow on Tuesday, April 27, 2021, at 9:00AM EDT. Achieve’s Chief Executive Officer, John Bencich, will be providing a corporate presentation and participating in a Q&A session with John Vandermosten, Senior Biotech Analyst at Zacks Small Cap Research.
To access the presentation, please visit https://www.issuerdirect.com/snn/ndr/achieve-life-sciences.
About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2
Achieve’s focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.
Cytisinicline is an investigational product candidate being developed for treatment of nicotine addiction, and has not been approved by the FDA for any indication in the U.S. Achieve is currently enrolling smokers in the 750-subject, Phase 3 ORCA-2 study of cytisinicline at 16 sites in the U.S. For more information on cytisinicline and the ORCA-2 study, visit www.achievelifesciences.com or www.orca-2.com.
About Zacks Small Cap Research
Zacks Small Cap Research focuses on small and micro-cap companies that are under followed or under valued by Wall Street. Our analysts seek to identify and report on these companies, bringing investors a unique opportunity to gain insight on small cap investments. Zacks SCR’s goal is to produce high quality, institutional research for the small cap investor.
About SNN.Network
SNN.Network is your multimedia financial news platform for discovery, transparency, and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the most up-to-date information on the Small-, Micro-, Nano-Cap market with the goal to help you towards achieving your wealth generation goals. Follow the companies YOU want to know more about; read and watch content from YOUR favorite finance and investing influencers; create YOUR own watchlist and screen for ideas YOU'RE interested in; find out about investor conferences YOU want to attend - all here on SNN.Network.
To access the presentation, please visit https://www.issuerdirect.com/snn/ndr/achieve-life-sciences.
About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2
Achieve’s focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.
Cytisinicline is an investigational product candidate being developed for treatment of nicotine addiction, and has not been approved by the FDA for any indication in the U.S. Achieve is currently enrolling smokers in the 750-subject, Phase 3 ORCA-2 study of cytisinicline at 16 sites in the U.S. For more information on cytisinicline and the ORCA-2 study, visit www.achievelifesciences.com or www.orca-2.com.
About Zacks Small Cap Research
Zacks Small Cap Research focuses on small and micro-cap companies that are under followed or under valued by Wall Street. Our analysts seek to identify and report on these companies, bringing investors a unique opportunity to gain insight on small cap investments. Zacks SCR’s goal is to produce high quality, institutional research for the small cap investor.
About SNN.Network
SNN.Network is your multimedia financial news platform for discovery, transparency, and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the most up-to-date information on the Small-, Micro-, Nano-Cap market with the goal to help you towards achieving your wealth generation goals. Follow the companies YOU want to know more about; read and watch content from YOUR favorite finance and investing influencers; create YOUR own watchlist and screen for ideas YOU'RE interested in; find out about investor conferences YOU want to attend - all here on SNN.Network.
Cytisinicline Up to Five Times More Likely to Result in Smoking Abstinence Compared to Placebo
Phase 3 ORCA-2 Trial Currently Enrolling at 16 sites in United States
SEATTLE, Wash and VANCOUVER, British Columbia, April 14, 2021 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced publication of the results from the Phase 2b ORCA-1 trial in the scientific journal Nicotine and Tobacco Research.
ORCA-1 evaluated the efficacy and safety of cytisinicline across various dosing and administration schedules in 254 smokers in the United States. The published results indicate that subjects treated with cytisinicline, regardless of dose or schedule, had statistically significantly higher (p<0.001) end of treatment abstinence rates compared to those treated with placebo. Participants in the 3.0 mg cytisinicline 3 times daily (TID) arm, were 5-times more likely to quit smoking than those in the placebo arm (OR of 5.04, 95% CI: 1.42, 22.32, p<0.001).
Cytisinicline was well-tolerated with no serious or severe adverse events (AEs) reported. Overall, in subjects treated with cytisinicline, all individual AE's reported were below a rate of 10%. In the 3.0 mg TID treatment arm versus placebo, the most common AEs were abnormal dreams, insomnia, and constipation (each 6% vs 2%), upper respiratory tract infections (6% vs 14%), and nausea (6% vs 10%). Adherence to study treatment was greater than 94% across all treatment arms and 98% in the 3.0 mg TID arm, specifically.
“As demonstrated in ORCA-1, cytisinicline is an efficacious and tolerable smoking cessation treatment that, when available, will be well-received by physicians and smokers who desperately need new cessation options,” stated Dr. Mitch Nides, ORCA-1 Primary Investigator. “The ongoing Phase 3 ORCA-2 trial is enrolling rapidly, and I would encourage those who are interested in quitting and who are near a trial location to consider participating.”
Healthcare providers, smokers, and their loved ones can learn more about how smokers can participate in the Phase 3 ORCA-2 trial by visiting www.orca-2.com.
About ORCA-1
ORCA-1 was the first study in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, which aims to evaluate the safety and effectiveness of cytisinicline for smoking cessation, nicotine addiction, and potentially other indications. The study was designed to evaluate the declining titration schedule, currently utilized in Central and Eastern Europe, compared to a simplified TID schedule at both the 1.5 mg and 3.0 mg cytisinicline doses compared to placebo. ORCA-1 topline results were announced in June 2019 and enrolled 254 smokers at eight centers across the United States.
To access the ORCA-1 publication, visit https://academic.oup.com/ntr/advance-article/doi/10.1093/ntr…
About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2
Achieve’s focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.
Cytisinicline is an investigational product candidate being developed for treatment of nicotine addiction, and has not been approved by the FDA for any indication in the U.S. Achieve is currently enrolling smokers in the 750-subject, Phase 3 ORCA-2 study of cytisinicline at 16 sites in the U.S. For more information on cytisinicline and the ORCA-2 study, visit www.achievelifesciences.com or www.orca-2.com.
Phase 3 ORCA-2 Trial Currently Enrolling at 16 sites in United States
SEATTLE, Wash and VANCOUVER, British Columbia, April 14, 2021 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced publication of the results from the Phase 2b ORCA-1 trial in the scientific journal Nicotine and Tobacco Research.
ORCA-1 evaluated the efficacy and safety of cytisinicline across various dosing and administration schedules in 254 smokers in the United States. The published results indicate that subjects treated with cytisinicline, regardless of dose or schedule, had statistically significantly higher (p<0.001) end of treatment abstinence rates compared to those treated with placebo. Participants in the 3.0 mg cytisinicline 3 times daily (TID) arm, were 5-times more likely to quit smoking than those in the placebo arm (OR of 5.04, 95% CI: 1.42, 22.32, p<0.001).
Cytisinicline was well-tolerated with no serious or severe adverse events (AEs) reported. Overall, in subjects treated with cytisinicline, all individual AE's reported were below a rate of 10%. In the 3.0 mg TID treatment arm versus placebo, the most common AEs were abnormal dreams, insomnia, and constipation (each 6% vs 2%), upper respiratory tract infections (6% vs 14%), and nausea (6% vs 10%). Adherence to study treatment was greater than 94% across all treatment arms and 98% in the 3.0 mg TID arm, specifically.
“As demonstrated in ORCA-1, cytisinicline is an efficacious and tolerable smoking cessation treatment that, when available, will be well-received by physicians and smokers who desperately need new cessation options,” stated Dr. Mitch Nides, ORCA-1 Primary Investigator. “The ongoing Phase 3 ORCA-2 trial is enrolling rapidly, and I would encourage those who are interested in quitting and who are near a trial location to consider participating.”
Healthcare providers, smokers, and their loved ones can learn more about how smokers can participate in the Phase 3 ORCA-2 trial by visiting www.orca-2.com.
About ORCA-1
ORCA-1 was the first study in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, which aims to evaluate the safety and effectiveness of cytisinicline for smoking cessation, nicotine addiction, and potentially other indications. The study was designed to evaluate the declining titration schedule, currently utilized in Central and Eastern Europe, compared to a simplified TID schedule at both the 1.5 mg and 3.0 mg cytisinicline doses compared to placebo. ORCA-1 topline results were announced in June 2019 and enrolled 254 smokers at eight centers across the United States.
To access the ORCA-1 publication, visit https://academic.oup.com/ntr/advance-article/doi/10.1093/ntr…
About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2
Achieve’s focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.
Cytisinicline is an investigational product candidate being developed for treatment of nicotine addiction, and has not been approved by the FDA for any indication in the U.S. Achieve is currently enrolling smokers in the 750-subject, Phase 3 ORCA-2 study of cytisinicline at 16 sites in the U.S. For more information on cytisinicline and the ORCA-2 study, visit www.achievelifesciences.com or www.orca-2.com.
Achieve Life Sciences Announces Presentation of Data on Smoker and E-Cigarette User Attitudes and Perceptions on Quitting at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
SEATTLE, Wash. and VANCOUVER, British Columbia, February 24, 2021 - Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that three posters featuring data on smoker and e-cigarette user behavior will be presented today, Wednesday, February 24th at the SRNT Annual Meeting being held virtually. An overview of the data can be also accessed by visiting https://ir.achievelifesciences.com/srnt2021.
SEATTLE, Wash. and VANCOUVER, British Columbia, February 24, 2021 - Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that three posters featuring data on smoker and e-cigarette user behavior will be presented today, Wednesday, February 24th at the SRNT Annual Meeting being held virtually. An overview of the data can be also accessed by visiting https://ir.achievelifesciences.com/srnt2021.
Antwort auf Beitrag Nr.: 66.916.505 von liquidx am 09.02.21 22:34:02kanns unter Biden nicht einschätzen, aber bislang wollte die fda hier den Wirkstoff unbdingt den Wirkstoff zu einer ZUlassung tragen... ich lass meine mal liegen ;-)
Achieve Life Sciences to Present at the MicroCap Rodeo Winter Wonderland Conference on February 16, 2021
SEATTLE, Wash and VANCOUVER, British Columbia / ACCESSWIRE / February 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will present at the MicroCap Rodeo Winter Wonderland Conference, which is being held virtually on February 16th – 19th, 2021.
Mr. John Bencich, Chief Executive Officer of Achieve Life Sciences, is scheduled to present on Tuesday, February 16th at 12:30 p.m. EST, with one-on-one meetings to be held throughout the conference.
The presentation will be webcast live and available for replay http://ir.achievelifesciences.com/events-and-webcasts. For registration information and meeting requests please visit https://microcaprodeo.com/signup.
About the MicroCap Rodeo Winter Wonderland Conference
The MicroCap Rodeo Winter Wonderland conference is a virtual event showcasing 35 best ideas from the buy side. Qualified institutional investors recommended each of the 35 companies represented.
About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2
Achieve’s focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.
As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.
SEATTLE, Wash and VANCOUVER, British Columbia / ACCESSWIRE / February 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will present at the MicroCap Rodeo Winter Wonderland Conference, which is being held virtually on February 16th – 19th, 2021.
Mr. John Bencich, Chief Executive Officer of Achieve Life Sciences, is scheduled to present on Tuesday, February 16th at 12:30 p.m. EST, with one-on-one meetings to be held throughout the conference.
The presentation will be webcast live and available for replay http://ir.achievelifesciences.com/events-and-webcasts. For registration information and meeting requests please visit https://microcaprodeo.com/signup.
About the MicroCap Rodeo Winter Wonderland Conference
The MicroCap Rodeo Winter Wonderland conference is a virtual event showcasing 35 best ideas from the buy side. Qualified institutional investors recommended each of the 35 companies represented.
About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2
Achieve’s focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.
As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.
Wie seht ihr die Lage hier?
Würdet ich nachlegen oder stehen eh keine News an in naher Zukunft?
Würdet ich nachlegen oder stehen eh keine News an in naher Zukunft?
Antwort auf Beitrag Nr.: 66.652.463 von freixenetter am 27.01.21 23:05:28bin mal raus plusminus 0
Antwort auf Beitrag Nr.: 66.612.179 von boss3 am 26.01.21 12:39:40klar, solange die fda den Wirkstoff unbedingt zulassen will, wird es auch weiter gehen
Antwort auf Beitrag Nr.: 66.553.097 von steve2007 am 21.01.21 22:50:41geht aber trotzdem weiter
Antwort auf Beitrag Nr.: 66.551.657 von boss3 am 21.01.21 21:18:23Boss 3 den Analysten musst du nicht glauben, habe ich nicht behauptet. Das Video ist aber vermutlich die Erklärung des heutigen Anstiegs. Musst dir nur Obseva und Dare bio anschauen die hat die Dame vor kurzen analysiert
Antwort auf Beitrag Nr.: 66.549.095 von steve2007 am 21.01.21 19:02:26also soll er ca bis in einem jahr zwischen
min.17,00 euro bis max ca 85 euro wachsen
naja wers glaubt wird selig
min.17,00 euro bis max ca 85 euro wachsen
naja wers glaubt wird selig
Antwort auf Beitrag Nr.: 66.549.011 von liquidx am 21.01.21 18:57:25habe ich was verpasst weil der anstieg so war
Der mögliche Grund
https://m.youtube.com/watch?v=6yXKpJjCCYk
https://m.youtube.com/watch?v=6yXKpJjCCYk
Was geht ab heute?
Antwort auf Beitrag Nr.: 65.944.566 von frus am 04.12.20 09:16:16kommt da was neues
Das ist der Grund: http://ir.achievelifesciences.com/2020-12-03-Achieve-Life-Sc…
Ja aber was ist der Grund?
Sieht gar nicht gut aus, ist noch jemand dabei?
Dies düfte der Grund sein.
http://ir.achievelifesciences.com/sec-filings
http://ir.achievelifesciences.com/sec-filings
DurchsuchenBeitrag schreiben
